aBLA Filing Intelligence & Biosimilar Opportunity

Kimmtrak

Tebentafusp-Tebn

Anticancer

Injection Injectable

Approval Date

25-Jan-22

Data Exclusivity Expiry

25-Jan-26

Market Exclusivity Expiry

25-Jan-34

Commercial snapshot

Market performance & projections

Revenue ($M)

401

CAGR (%)

0.1146

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

443

2027

495

2028

543

2029

619

2030

696

2031

722

2032

795

Molecule profile

Details & specifications

Molecule

Tebentafusp-Tebn

Innovator

IMMUNOCORE COMMERCIAL LLC

Dosage Form

Injection Injectable

Strength

100 mcg/0.5 mL

Therapeutic Category

Anticancer

Usage

To treat unresectable or metastatic uveal melanoma

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.